Identification

Name
Doxepin
Accession Number
DB01142  (APRD00398)
Type
Small Molecule
Groups
Approved
Description

Doxepin hydrochloride is a dibenzoxepin-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, doxepin does not affect mood or arousal, but may cause sedation. In depressed individuals, doxepin exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as doxepin and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Doxepin has less sedative and anticholinergic effects than amitriptyline. See toxicity section below for a complete listing of side effects. Doxepin may be used to treat depression and insomnia. Unlabeled indications include chronic and neuropathic pain, and anxiety. Doxepin may also be used as a second line agent to treat idiopathic urticaria.

Structure
Thumb
Synonyms
  • Cidoxepin
  • Doxepin
Product Ingredients
IngredientUNIICASInChI Key
Cidoxepin hydrochlorideXI27WMG8QK25127-31-5MHNSPTUQQIYJOT-CULRIWENSA-N
Doxepin Hydrochloride3U9A0FE9N51229-29-4MHNSPTUQQIYJOT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-doxepin - Cap 10mgCapsule10 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-doxepin-cap 25mgCapsule25 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-doxepin-cap 50mgCapsule50 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-doxepin-cap 75mgCapsule75 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Doxepin HydrochlorideCream50 mg/gTopicalRenaissance Pharma, Inc.2016-03-07Not applicableUs
Doxepine-10 - CapCapsule10 mgOralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-100 - CapCapsule100 mgOralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-150 - CapCapsule150 mgOralPro Doc Limitee1995-12-312009-07-23Canada
Doxepine-25 -capCapsule25 mgOralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-50 - CapCapsule50 mgOralPro Doc Limitee1995-12-312010-07-13Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-doxepinCapsule25 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-doxepinCapsule10 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-doxepinCapsule50 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-doxepinCapsule100 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-doxepinCapsule75 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-doxepinCapsule150 mgOralApotex Corporation1993-12-31Not applicableCanada
Doxepin HydrochlorideSolution, concentrate10 mg/mLOralTeva1987-11-062016-07-31Us
Doxepin HydrochlorideSolution10 mg/mLOralMorton Grove Pharmaceuticals, Inc.1995-02-09Not applicableUs
Doxepin HydrochlorideCapsule75 mg/1OralContract Pharmacy Services Pa2010-04-06Not applicableUs
Doxepin HydrochlorideCapsule100 mg/1OralRemedy Repack2006-11-24Not applicableUs
International/Other Brands
Adapin (PennwaIt) / Aponal (Pfizer) / Curatin / Doxepine (Shou Chan) / Quitaxon (Lexphar) / Sinequan (Pfizer) / Zonalon
Categories
UNII
F96TTB8728
CAS number
1668-19-5
Weight
Average: 279.3761
Monoisotopic: 279.162314299
Chemical Formula
C19H21NO
InChI Key
ODQWQRRAPPTVAG-BOPFTXTBSA-N
InChI
InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-
IUPAC Name
dimethyl(3-{9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12

Pharmacology

Indication

Doxepin is used for the treatment of depression and/or anxiety. It can also be used for chronic urticaria and in the management of pain.

Structured Indications
Pharmacodynamics

Doxepin, a tricyclic antidepressant of the dibenzoxepin type, is used to treat depression and anxiety and, topically, pruritus associated with eczema. Doxepin has substantial anticholinergic and sedative effects. The E (trans)-isomer is more active as a serotonin reuptake inhibitor while the Z-isomer acts as a sedative.

Mechanism of action

The mechanism of action of doxepin is not completely understood. It is thought that like amitriptyline, doxepin enhances the actions of norepinephrine and serotonin by blocking their reuptake at the neuronal membrane. However, doxepin weakly inhibits the reuptake of dopamine. Doxepin may also act on histamine H1-receptors, resulting in sedative effects, and β-adrenergic receptors. It is also an antagonist of 5-hydroxytryptamine (serotonin) receptors, alpha-1 adrenergic receptor, and muscarinic cholinergic receptors.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
AHistamine H2 receptor
antagonist
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 2B
antagonist
Human
A5-hydroxytryptamine receptor 2C
antagonist
Human
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M3
antagonist
Human
AMuscarinic acetylcholine receptor M4
antagonist
Human
AMuscarinic acetylcholine receptor M5
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
A5-hydroxytryptamine receptor 1A
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 6
binder
Human
UHistamine H4 receptor
binder
Human
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
Absorption

Well-absorbed from the GI tract. Peak plasma concentrations occur within 2 hours of oral administration.

Volume of distribution
Not Available
Protein binding

Doxepin and desmethyldoxepin is 80% protein bound. It is also a lipophillic drug and is capable of crossing the blood-brain-barrier.

Metabolism

Extensively metabolized in the liver via the same pathways as other TCAs. N-demethylation produces an active metabolite, N-desmethyldoxepin. CYP2D6 specifically hydroxylates the E-isomer.

Route of elimination
Not Available
Half life

6 - 24.5 hours

Clearance
Not Available
Toxicity

LD50=26 (mg/kg) (in mice, iv); LD50=16 (mg/kg) (in rats, iv); Cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Doxepin Metabolism PathwayDrug metabolism
Doxepin H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with poor metabolism of doxepin.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of doxepin.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Doxepin can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Doxepin.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Doxepin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxepin.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Doxepin can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxepin.Experimental, Illicit
4-MethoxyamphetamineDoxepin may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Doxepin.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Doxepin.Experimental
AbirateroneThe serum concentration of Doxepin can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Doxepin.Approved
AcenocoumarolDoxepin may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Doxepin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Doxepin.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Doxepin.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Doxepin.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Doxepin.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Doxepin.Approved
AgmatineDoxepin may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doxepin.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Doxepin is combined with Alaproclate.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Doxepin.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Doxepin.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Doxepin.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Doxepin.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Doxepin.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Doxepin.Approved, Investigational
AlogliptinThe serum concentration of Doxepin can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Doxepin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Doxepin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Doxepin.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Doxepin.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Doxepin.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Doxepin.Approved, Investigational
AmiodaroneThe metabolism of Doxepin can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doxepin.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxepin.Approved
AmobarbitalThe metabolism of Doxepin can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Doxepin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Doxepin.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Doxepin.Approved, Illicit
AmprenavirThe serum concentration of Doxepin can be increased when it is combined with Amprenavir.Approved
AnagrelideDoxepin may increase the QTc-prolonging activities of Anagrelide.Approved
Antithrombin III humanThe serum concentration of Doxepin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Doxepin can be increased when it is combined with Apixaban.Approved
ApomorphineDoxepin may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineDoxepin may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Doxepin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Doxepin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Doxepin can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doxepin.Approved, Investigational
ArmodafinilThe metabolism of Doxepin can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideDoxepin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDoxepin may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Doxepin.Approved
AsenapineDoxepin may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Doxepin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Doxepin.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Doxepin.Approved
AtomoxetineThe metabolism of Doxepin can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Doxepin.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Doxepin.Vet Approved
AzelastineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinDoxepin may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Doxepin.Approved
BambuterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Bambuterol.Approved
BarbexacloneThe metabolism of Doxepin can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Doxepin can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Doxepin can be increased when it is combined with Batimastat.Experimental
BedaquilineDoxepin may increase the QTc-prolonging activities of Bedaquiline.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Doxepin.Approved, Investigational
BenazeprilThe serum concentration of Doxepin can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Doxepin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Doxepin.Investigational
BenzamidineThe serum concentration of Doxepin can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Doxepin.Approved
BenzphetamineDoxepin may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Doxepin.Approved
Benzylpenicilloyl PolylysineDoxepin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Doxepin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Doxepin.Approved, Vet Approved
BetaxololThe metabolism of Doxepin can be decreased when combined with Betaxolol.Approved
BethanidineDoxepin may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Doxepin is combined with Bifeprunox.Investigational
BivalirudinThe serum concentration of Doxepin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Doxepin can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Doxepin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Doxepin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Doxepin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxepin.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Doxepin.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Doxepin.Experimental
BromocriptineDoxepin may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Doxepin is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxepin.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Doxepin.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxepin.Approved, Investigational
BuprenorphineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Doxepin can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Doxepin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doxepin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Doxepin.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Doxepin.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Doxepin.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Doxepin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doxepin.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Doxepin.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Doxepin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Doxepin.Approved
CamostatThe serum concentration of Doxepin can be increased when it is combined with Camostat.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Doxepin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Doxepin.Approved
CandoxatrilThe serum concentration of Doxepin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Doxepin can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Doxepin.Investigational
CapecitabineThe metabolism of Doxepin can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Doxepin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Doxepin can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Doxepin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Doxepin.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Doxepin.Approved
CariprazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Doxepin.Withdrawn
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Doxepin.Approved
CefpodoximeDoxepin can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeDoxepin can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CelecoxibThe metabolism of Doxepin can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Doxepin is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Doxepin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Doxepin.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Doxepin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Doxepin.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Doxepin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doxepin.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Doxepin.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doxepin.Approved
ChloroquineDoxepin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxepin.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Doxepin.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorproethazine.Experimental
ChlorpromazineDoxepin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doxepin.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Doxepin.Approved
CholecalciferolThe metabolism of Doxepin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Doxepin can be increased when it is combined with Cholesterol.Experimental
ChymostatinThe serum concentration of Doxepin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Doxepin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Doxepin can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Doxepin can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Doxepin can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doxepin.Approved, Vet Approved
CiprofloxacinDoxepin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineDoxepin may increase the vasopressor activities of Cirazoline.Experimental
CisaprideDoxepin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Doxepin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.Approved
ClarithromycinThe metabolism of Doxepin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Doxepin can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Clenbuterol.Approved, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Doxepin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Doxepin.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Doxepin.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Doxepin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Doxepin.Approved, Illicit
ClonidineDoxepin may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Doxepin.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Doxepin.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.Approved, Illicit
ClorindioneDoxepin may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Doxepin.Experimental
ClotrimazoleThe metabolism of Doxepin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineDoxepin may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Doxepin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Doxepin.Approved
CocaineThe metabolism of Doxepin can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Doxepin.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Doxepin.Approved
ConivaptanThe serum concentration of Doxepin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Doxepin.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Doxepin.Approved
CrisaboroleThe metabolism of Doxepin can be decreased when combined with Crisaborole.Approved
CrizotinibDoxepin may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Doxepin is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.Approved
CyclosporineThe metabolism of Doxepin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Doxepin.Approved
Cyproterone acetateThe serum concentration of Doxepin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Doxepin.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxepin.Approved
DabrafenibThe serum concentration of Doxepin can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Doxepin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Doxepin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doxepin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Doxepin.Investigational
DarexabanThe serum concentration of Doxepin can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Doxepin can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Doxepin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Doxepin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Doxepin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Doxepin.Approved
DeferasiroxThe serum concentration of Doxepin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Doxepin can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Doxepin can be increased when it is combined with Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Doxepin.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Doxepin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Doxepin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Doxepin.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Doxepin.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin.Approved
DexmedetomidineDoxepin may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Doxepin.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Doxepin.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Doxepin.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Doxepin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doxepin.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Doxepin.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Doxepin.Approved, Illicit, Vet Approved
DicoumarolDoxepin may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Doxepin.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Doxepin.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxepin.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Doxepin is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Doxepin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Doxepin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxepin.Approved, Illicit
DihydroergotamineDoxepin may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doxepin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doxepin.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Doxepin.Illicit
DiltiazemThe metabolism of Doxepin can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxepin.Approved
DiphenadioneDoxepin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Doxepin can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doxepin.Approved, Illicit
DipivefrinDoxepin may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Doxepin.Approved
DisopyramideDoxepin may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Doxepin.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Doxepin.Approved, Investigational
DofetilideDoxepin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDoxepin may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneDoxepin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Doxepin.Vet Approved
DosulepinThe metabolism of Doxepin can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Doxepin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Doxepin.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Illicit
DronedaroneDoxepin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Doxepin.Experimental, Illicit
DroxidopaDoxepin may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Doxepin.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin.Approved
EcabetThe serum concentration of Doxepin can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Doxepin.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Doxepin.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Doxepin.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Doxepin.Approved, Investigational
ElafinThe serum concentration of Doxepin can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Doxepin.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Doxepin.Approved, Investigational
EliglustatDoxepin may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Doxepin.Investigational
EnalaprilThe serum concentration of Doxepin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Doxepin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Doxepin can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Doxepin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Doxepin.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Doxepin.Approved, Investigational
EnzalutamideThe serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.Approved
EphedraDoxepin may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Doxepin can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Doxepin.Approved, Investigational
EpinephrineDoxepin may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Doxepin is combined with Ergonovine.Approved
ErgotamineDoxepin may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Doxepin.Approved, Investigational
ErythromycinDoxepin may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Doxepin can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Doxepin can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Doxepin.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Doxepin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Doxepin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Doxepin.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doxepin.Approved
EthanolDoxepin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxepin.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxepin.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxepin.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doxepin.Approved
Ethyl biscoumacetateDoxepin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doxepin.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Doxepin.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Doxepin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doxepin.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Doxepin.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Doxepin.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Doxepin.Approved
EtomidateDoxepin may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Doxepin.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Doxepin.Illicit, Vet Approved
EtravirineThe metabolism of Doxepin can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxepin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Doxepin.Approved
EzogabineThe risk or severity of adverse effects can be increased when Doxepin is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Doxepin can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Doxepin.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Doxepin.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxepin.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseDoxepin can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateDoxepin can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateDoxepin can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Doxepin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Doxepin.Approved
FlecainideDoxepin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flibanserin.Approved
FloxuridineThe metabolism of Doxepin can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Doxepin.Experimental
FluconazoleThe metabolism of Doxepin can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Doxepin.Approved, Illicit
FluindioneDoxepin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Doxepin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Doxepin.Approved, Illicit
FluorouracilThe metabolism of Doxepin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Doxepin.Approved, Vet Approved
FlupentixolDoxepin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Doxepin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doxepin.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Doxepin.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxepin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Doxepin.Approved
FluvastatinThe metabolism of Doxepin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doxepin.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Doxepin.Approved
FosaprepitantThe serum concentration of Doxepin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Doxepin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Doxepin can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Doxepin.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Doxepin.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Doxepin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Doxepin can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Doxepin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Doxepin is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Doxepin can be increased when it is combined with Gabexate.Investigational
Gadobenic acidDoxepin may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Doxepin.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Doxepin.Approved, Investigational
GeldanamycinThe serum concentration of Doxepin can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Doxepin.Approved
GemfibrozilThe metabolism of Doxepin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinDoxepin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Doxepin.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Doxepin.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Doxepin.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Doxepin.Approved, Illicit
GM6001The serum concentration of Doxepin can be increased when it is combined with GM6001.Experimental
GoserelinDoxepin may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronDoxepin may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Doxepin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Doxepin.Withdrawn
GuanabenzDoxepin may decrease the antihypertensive activities of Guanabenz.Approved
GuanfacineDoxepin may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Doxepin.Approved, Illicit, Withdrawn
HaloperidolDoxepin may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Doxepin.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Doxepin.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Doxepin.Approved, Illicit
HexobarbitalThe metabolism of Doxepin can be increased when combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxepin.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Doxepin.Experimental
HydrocodoneDoxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Doxepin.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Doxepin.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Doxepin.Approved
IbutilideDoxepin may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Doxepin can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Doxepin can be increased when it is combined with Idraparinux.Investigational
IloperidoneDoxepin may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Doxepin can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Doxepin can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Doxepin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Doxepin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Doxepin is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Doxepin.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Doxepin.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Doxepin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Doxepin.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Doxepin.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Doxepin.Approved
IproclozideIproclozide may increase the serotonergic activities of Doxepin.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Doxepin.Withdrawn
IrbesartanThe metabolism of Doxepin can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Doxepin.Approved, Investigational
IronDoxepin can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranDoxepin can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateDoxepin can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Doxepin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Doxepin is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Doxepin is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Doxepin.Approved, Vet Approved
IsoflurophateThe serum concentration of Doxepin can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Doxepin can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Isoprenaline.Approved
IsradipineThe metabolism of Doxepin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Doxepin.Approved, Investigational
IvacaftorThe serum concentration of Doxepin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Doxepin.Approved, Vet Approved
IxazomibThe serum concentration of Doxepin can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxepin.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Doxepin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doxepin.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Doxepin.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Doxepin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Doxepin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Doxepin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Doxepin.Approved
LeflunomideThe metabolism of Doxepin can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Doxepin.Approved
LenvatinibDoxepin may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Doxepin can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Doxepin can be increased when it is combined with Letaxaban.Investigational
LeuprolideDoxepin may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Doxepin.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Doxepin.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Doxepin is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Doxepin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Doxepin is combined with Levodopa.Approved
LevofloxacinDoxepin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doxepin.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.Approved
LevonordefrinDoxepin may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doxepin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Doxepin is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Doxepin.Approved
LidocaineThe metabolism of Doxepin can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Doxepin can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Doxepin.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Doxepin.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Doxepin.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Doxepin.Approved, Investigational
LisinoprilThe serum concentration of Doxepin can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Doxepin.Approved
LobeglitazoneThe metabolism of Doxepin can be decreased when combined with Lobeglitazone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Doxepin.Illicit
LofexidineDoxepin may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Doxepin.Approved
LopinavirThe metabolism of Doxepin can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Doxepin.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Doxepin.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Doxepin.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Doxepin is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Doxepin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Doxepin.Approved
LovastatinThe metabolism of Doxepin can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Doxepin.Approved
LuliconazoleThe serum concentration of Doxepin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Doxepin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineDoxepin may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Vet Approved
ManidipineThe metabolism of Doxepin can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Doxepin.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doxepin.Approved
MebanazineMebanazine may increase the serotonergic activities of Doxepin.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Doxepin.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Doxepin.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Doxepin.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Doxepin.Vet Approved
MelagatranThe serum concentration of Doxepin can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Doxepin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Doxepin.Approved
MephedroneMephedrone may decrease the sedative activities of Doxepin.Investigational
MephentermineDoxepin may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doxepin.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Doxepin.Experimental
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doxepin.Approved
MetaraminolDoxepin may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Doxepin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Doxepin.Approved, Illicit
MethamphetamineDoxepin may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Doxepin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Doxepin.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.Approved, Vet Approved
MethohexitalThe metabolism of Doxepin can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Doxepin.Approved
MethotrimeprazineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineDoxepin may increase the vasopressor activities of Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doxepin.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Doxepin.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Doxepin is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Doxepin.Experimental
Methylene blueDoxepin may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.Approved, Investigational
MethylphenobarbitalThe metabolism of Doxepin can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Doxepin.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Doxepin.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Doxepin.Approved, Investigational
MetyrosineDoxepin may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Doxepin can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Doxepin.Approved, Illicit
MidodrineDoxepin may increase the vasopressor activities of Midodrine.Approved
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Doxepin.Experimental, Illicit
MidostaurinThe metabolism of Doxepin can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Doxepin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Doxepin is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Doxepin.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Doxepin.Approved
MirtazapineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Doxepin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Doxepin.Approved, Investigational
MMDAMMDA may decrease the sedative activities of Doxepin.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Doxepin is combined with Moclobemide.Approved
ModafinilThe metabolism of Doxepin can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Doxepin can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Doxepin.Approved
MoperoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Moperone.Experimental
MorphineThe serum concentration of Morphine can be increased when it is combined with Doxepin.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Mosapramine.Experimental
MoxifloxacinDoxepin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Doxepin.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxepin.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Doxepin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Doxepin.Approved
NafamostatThe serum concentration of Doxepin can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doxepin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxepin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Doxepin.Approved, Vet Approved
NaphazolineDoxepin may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Doxepin.Approved, Investigational
NefazodoneThe metabolism of Doxepin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Doxepin.Approved
NetupitantThe serum concentration of Doxepin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Doxepin can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Doxepin.Withdrawn
NicardipineThe metabolism of Doxepin can be decreased when combined with Nicardipine.Approved
NicorandilDoxepin may increase the hypotensive activities of Nicorandil.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Doxepin.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Doxepin.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Doxepin.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doxepin.Approved
NitroaspirinThe serum concentration of Doxepin can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Doxepin.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Doxepin.Approved
NorepinephrineDoxepin may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Doxepin.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Doxepin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Doxepin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Doxepin.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Doxepin.Investigational
OfloxacinDoxepin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Doxepin.Approved, Investigational
OlaparibThe metabolism of Doxepin can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doxepin.Approved
OmapatrilatThe serum concentration of Doxepin can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Doxepin.Approved
OmeprazoleThe metabolism of Doxepin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronDoxepin may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Doxepin.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Orciprenaline.Approved
OrphenadrineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Doxepin.Investigational
OsimertinibThe serum concentration of Doxepin can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Doxepin can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doxepin.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Doxepin.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doxepin.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Doxepin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxepin.Approved, Illicit, Investigational
OxymetazolineDoxepin may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxepin.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Doxepin is combined with Oxypertine.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Doxepin.Approved, Vet Approved
PalbociclibThe serum concentration of Doxepin can be increased when it is combined with Palbociclib.Approved
PaliperidoneDoxepin may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Doxepin.Approved, Investigational
PanobinostatThe serum concentration of Doxepin can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Doxepin can be decreased when combined with Pantoprazole.Approved
ParaldehydeDoxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the serotonergic activities of Doxepin.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Doxepin.Approved
Peginterferon alfa-2bThe serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Doxepin.Experimental
PentamidineDoxepin may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.Approved, Vet Approved
PentobarbitalThe metabolism of Doxepin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Doxepin.Investigational
PerflutrenDoxepin may increase the QTc-prolonging activities of Perflutren.Approved
PergolideDoxepin may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Doxepin can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Doxepin.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Doxepin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Doxepin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Doxepin.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Doxepin.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Doxepin.Experimental
PhenindioneDoxepin may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Doxepin.Withdrawn
PhenobarbitalThe metabolism of Doxepin can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Doxepin.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Doxepin.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Doxepin.Withdrawn
PhenprocoumonDoxepin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may decrease the sedative activities of Doxepin.Approved, Illicit
PhenylephrineDoxepin may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineDoxepin may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Doxepin can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Doxepin can be increased when it is combined with Phosphoramidon.Experimental
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Doxepin.Approved
PimozideDoxepin may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doxepin.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Doxepin.Investigational
PirlindolePirlindole may increase the serotonergic activities of Doxepin.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Doxepin.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Doxepin.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Doxepin is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Doxepin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Doxepin.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Doxepin.Approved, Investigational, Vet Approved
PramipexoleDoxepin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Doxepin.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Doxepin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Doxepin.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Doxepin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Doxepin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Doxepin.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Doxepin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Doxepin.Approved
PrimaquineDoxepin may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Doxepin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Doxepin can be increased when it is combined with Prinomastat.Investigational
ProcainamideDoxepin may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Doxepin.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxepin.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Doxepin.Approved, Vet Approved
PromazineDoxepin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Doxepin.Approved
PropafenoneDoxepin may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Doxepin.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Doxepin.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Doxepin.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Doxepin.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Doxepin.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Doxepin is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Doxepin.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Doxepin.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Doxepin.Investigational
PseudoephedrineDoxepin may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Doxepin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Doxepin.Approved, Illicit
QuetiapineDoxepin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Doxepin can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineDoxepin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineDoxepin may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Doxepin.Experimental
RacecadotrilThe serum concentration of Doxepin can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Doxepin.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Doxepin.Approved, Investigational
RamiprilThe serum concentration of Doxepin can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Doxepin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Doxepin.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Doxepin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxepin.Approved
RemikirenThe serum concentration of Doxepin can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doxepin.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Doxepin.Approved
RifabutinThe metabolism of Doxepin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Doxepin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Doxepin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Doxepin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Doxepin.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Doxepin.Approved, Investigational
RisperidoneDoxepin may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Doxepin.Investigational
RitobegronRitobegron may decrease the sedative activities of Doxepin.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Doxepin is combined with Ritodrine.Approved
RitonavirThe metabolism of Doxepin can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Doxepin can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Doxepin.Approved
RolapitantThe metabolism of Doxepin can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Doxepin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Doxepin.Vet Approved
RopiniroleDoxepin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxepin.Approved
RotigotineDoxepin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin.Approved
S-3304The serum concentration of Doxepin can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Doxepin.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Doxepin is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Doxepin.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Doxepin.Approved, Investigational
SaxagliptinThe serum concentration of Doxepin can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.Approved
SecobarbitalThe metabolism of Doxepin can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Doxepin.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Doxepin.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Doxepin.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Doxepin.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Doxepin.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxepin.Approved, Vet Approved
SildenafilThe metabolism of Doxepin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Doxepin.Approved
SiltuximabThe serum concentration of Doxepin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Doxepin can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Doxepin can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Doxepin can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Doxepin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Doxepin.Approved, Investigational
SotalolDoxepin may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxepin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Doxepin.Experimental
SpiraprilThe serum concentration of Doxepin can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Doxepin can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Doxepin can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.Approved, Investigational
SulfadiazineThe metabolism of Doxepin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Doxepin can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Doxepin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doxepin.Approved
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Doxepin.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Doxepin.Approved, Investigational
SuvorexantDoxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Doxepin.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Doxepin.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Doxepin.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Doxepin is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Doxepin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Doxepin.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Doxepin.Approved
TelaprevirThe metabolism of Doxepin can be decreased when combined with Telaprevir.Withdrawn
TelavancinDoxepin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Doxepin can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Doxepin.Approved
TemocaprilThe serum concentration of Doxepin can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Doxepin.Approved
Tenofovir disoproxilThe metabolism of Doxepin can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineDoxepin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Doxepin.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Doxepin.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Doxepin.Investigational
ThalidomideDoxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Doxepin can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Doxepin can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Doxepin can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Doxepin is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Doxepin.Withdrawn
ThiorphanThe serum concentration of Doxepin can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doxepin.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Doxepin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Doxepin.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Doxepin.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Doxepin.Approved
TiclopidineThe metabolism of Doxepin can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Doxepin.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Doxepin.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Doxepin.Approved
TioclomarolDoxepin may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Doxepin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineDoxepin may decrease the antihypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Doxepin can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Doxepin can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxepin.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Doxepin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Doxepin.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxepin.Approved
TopiroxostatThe metabolism of Doxepin can be decreased when combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Doxepin.Approved, Investigational
ToremifeneDoxepin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolDoxepin may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Doxepin can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Doxepin.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doxepin.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Doxepin.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Doxepin.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Doxepin.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Doxepin.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Doxepin.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doxepin.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Doxepin.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doxepin.Approved, Vet Approved
TrimethoprimThe metabolism of Doxepin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Doxepin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Doxepin.Approved
TropisetronTropisetron may increase the serotonergic activities of Doxepin.Approved, Investigational
UbenimexThe serum concentration of Doxepin can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Doxepin can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Doxepin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Doxepin.Approved
Valproic AcidThe serum concentration of Doxepin can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Doxepin can be decreased when combined with Valsartan.Approved, Investigational
VandetanibDoxepin may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Doxepin.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Doxepin.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Doxepin.Approved
VemurafenibThe serum concentration of Doxepin can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Doxepin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Doxepin.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Doxepin.Experimental
VerapamilThe metabolism of Doxepin can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Doxepin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Doxepin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Doxepin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Doxepin.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Doxepin.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Doxepin.Approved
VoriconazoleThe metabolism of Doxepin can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Doxepin is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Doxepin.Approved
WarfarinDoxepin may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Doxepin.Experimental
XimelagatranThe serum concentration of Doxepin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Doxepin.Vet Approved
XylometazolineDoxepin may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Doxepin.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Doxepin can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Doxepin can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doxepin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Doxepin.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Doxepin is combined with Zimelidine.Withdrawn
ZiprasidoneDoxepin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Doxepin can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Doxepin.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Doxepin.Approved, Investigational
ZolpidemDoxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Doxepin.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Doxepin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Doxepin.Approved
ZucapsaicinThe metabolism of Doxepin can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolDoxepin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.

References

Synthesis Reference

Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Casseday, Meredith Perry, Bryan Knox, "LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME." U.S. Patent US20090074862, issued March 19, 2009.

US20090074862
General References
  1. Virtanen R, Iisalo E, Irjala K: Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh). 1982 Aug;51(2):159-64. [PubMed:7113722]
  2. Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6. [PubMed:7293791]
  3. Negro-Alvarez JM, Carreno-Rojo A, Funes-Vera E, Garcia-Canovas A, Abellan-Aleman AF, Rubio del Barrio R: Pharmacologic therapy for urticaria. Allergol Immunopathol (Madr). 1997 Jan-Feb;25(1):36-51. [PubMed:9111875]
  4. Sansone RA, Sansone LA: Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008 Dec;5(12):16-9. [PubMed:19724772]
  5. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]
External Links
KEGG Drug
D07875
KEGG Compound
C06971
PubChem Compound
667468
PubChem Substance
46505232
ChemSpider
580850
BindingDB
50079527
ChEBI
36691
ChEMBL
CHEMBL101740
Therapeutic Targets Database
DAP000177
PharmGKB
PA449409
IUPHAR
1225
Guide to Pharmacology
GtP Drug Page
HET
D7V
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Doxepin
ATC Codes
N06AA12 — Doxepin
AHFS Codes
  • 28:16.04.28
  • 84:08.00
PDB Entries
Not Available
FDA label
Download (588 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentParkinson's Disease (PD) / Sleeplessness1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentSleep Initiation and Maintenance Disorders1
2RecruitingPreventionCancer, Breast1
3Active Not RecruitingSupportive CareHead and Neck Carcinoma / Mucositis / Oral Complications of Radiation Therapy / Pain1
3CompletedTreatmentAcute Oral Mucositis Pain1
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sleeplessness1
4Unknown StatusDiagnosticHealthy Volunteers1
Not AvailableActive Not RecruitingSupportive CareAdvanced thymic carcinoma / Hypopharyngeal Carcinoma / Laryngeal Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Lymphomas / Malignant Pericardial Effusion / Malignant Pleural Effusions / Mesothelioma / Mesothelioma, Malignant / Metastatic Malignant Neoplasm in the Lung / Metastatic Malignant Neoplasm in the Pleura / Metastatic Malignant Neoplasm in the Spinal Cord / Non-Small Cell Lung Carcinoma (NSCLC) / Oesophageal Carcinoma / Sarcomas / Small Cell Lung Carcinoma / Soft Tissue Sarcoma (STS) / Thymic Carcinoma / Thymoma and Thymic Carcinoma / Thyroid Gland Carcinoma1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral100 mg
CapsuleOral25 mg
CapsuleOral50 mg
CapsuleOral75 mg
CapsuleOral10 mg/1
CapsuleOral100 mg/1
CapsuleOral150 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
SolutionOral10 mg/mL
Solution, concentrateOral10 mg/mL
CapsuleOral150 mg
TabletOral3 mg/1
TabletOral3.00 mg
TabletOral6 mg/1
TabletOral6.00 mg
CreamTopical50 mg/g
CreamTopical5 %
Prices
Unit descriptionCostUnit
Zonalon 5% Cream 45 gm Tube190.13USD tube
Zonalon 5% Cream 30 gm Tube144.29USD tube
Doxepin hcl powder8.88USD g
Doxepin 150 mg capsule3.33USD capsule
Prudoxin 5% cream3.05USD g
Sinequan 100 mg Capsule1.22USD capsule
Novo-Doxepin 150 mg Capsule1.18USD capsule
Sinequan 75 mg Capsule0.93USD capsule
Zonalon 5% cream0.89USD g
Doxepin HCl 150 mg capsule0.87USD capsule
Apo-Doxepin 100 mg Capsule0.68USD capsule
Novo-Doxepin 100 mg Capsule0.68USD capsule
Sinequan 50 mg Capsule0.64USD capsule
Doxepin 50 mg capsule0.57USD capsule
Doxepin HCl 100 mg capsule0.56USD capsule
Novo-Doxepin 75 mg Capsule0.52USD capsule
Apo-Doxepin 75 mg Capsule0.52USD capsule
Doxepin HCl 75 mg capsule0.43USD capsule
Apo-Doxepin 50 mg Capsule0.36USD capsule
Novo-Doxepin 50 mg Capsule0.36USD capsule
Sinequan 25 mg Capsule0.35USD capsule
Doxepin 10 mg capsule0.32USD capsule
Sinequan 10 mg Capsule0.28USD capsule
Doxepin HCl 50 mg capsule0.25USD capsule
Doxepin HCl 25 mg capsule0.23USD capsule
Doxepin 75 mg capsule0.21USD capsule
Doxepin HCl 10 mg capsule0.21USD capsule
Apo-Doxepin 10 mg Capsule0.2USD capsule
Apo-Doxepin 25 mg Capsule0.19USD capsule
Novo-Doxepin 25 mg Capsule0.19USD capsule
Doxepin 25 mg capsule0.18USD capsule
Doxepin 100 mg capsule0.14USD capsule
Doxepin HCl 10 mg/ml Concentrate0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6211229No2000-02-172020-02-17Us
US9107898No2008-05-012028-05-01Us
US8513299No2010-04-142030-04-14Us
US7915307No2007-08-242027-08-24Us
US9532971No2009-06-012029-06-01Us
US9486437No2007-05-182027-05-18Us
US9572814No2007-07-202027-07-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)265 °C at 2.00E-01 mm HgPhysProp
water solubility31.6 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.29SANGSTER (1994)
logS-3.4ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0319 mg/mLALOGPS
logP4.08ALOGPS
logP3.84ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity98.24 m3·mol-1ChemAxon
Polarizability32.47 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9931
Blood Brain Barrier+0.9381
Caco-2 permeable+0.8108
P-glycoprotein substrateSubstrate0.8147
P-glycoprotein inhibitor IInhibitor0.8147
P-glycoprotein inhibitor IIInhibitor0.8214
Renal organic cation transporterInhibitor0.7883
CYP450 2C9 substrateNon-substrate0.7846
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7475
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.917
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6362
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8322
BiodegradationNot ready biodegradable0.8461
Rat acute toxicity3.2478 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5346
hERG inhibition (predictor II)Inhibitor0.6959
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0090000000-c6d70f4744a166243d9c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1290000000-843ca75cae9c06d5a947
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-3940000000-053eb0b8a655ffc47644
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-3920000000-1decbf30162661f4429b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-4920000000-7a9368d04bc38800e87e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05ox-4920000000-e6f843926675f1d98789
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016r-4910000000-1ea8272c7a2859f70a82
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-4910000000-567d6be4466beea7456e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014r-4900000000-ce29d6e3479d635e3995

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxepines
Sub Class
Dibenzoxepines
Direct Parent
Dibenzoxepines
Alternative Parents
Alkyl aryl ethers / Benzenoids / Trialkylamines / Oxacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzoxepine / Alkyl aryl ether / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Oxacycle / Ether / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, dibenzooxepine (CHEBI:4710)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093]
  2. Tran VT, Lebovitz R, Toll L, Snyder SH: [3H]doxepin interactions with histamine H1-receptors and other sites in guinea pig and rat brain homogenates. Eur J Pharmacol. 1981 Apr 9;70(4):501-9. [PubMed:7238574]
  3. Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K: Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci. 2004 Aug;20(3):803-10. [PubMed:15255990]
  4. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. [PubMed:3011460]
  5. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  6. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  7. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
  8. Singh H, Becker PM: Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. [PubMed:17685877]
  9. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Histamine H2 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Beil W, Hannemann H, Sewing KF: Interaction of antidepressants and neuroleptics with histamine stimulated parietal cell adenylate cyclase and H+ secretion. Pharmacology. 1988;36(3):198-203. [PubMed:2897127]
  2. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138]
  3. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
  3. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499]
  4. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941]
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. PDSP Ki Database [Link]
Details
22. Histamine H4 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Histamine receptor activity
Specific Function
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agoni...
Gene Name
HRH4
Uniprot ID
Q9H3N8
Uniprot Name
Histamine H4 receptor
Molecular Weight
44495.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC: Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol. 2007 Aug 1;74(3):425-37. Epub 2007 May 3. [PubMed:17560554]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Szewczuk-Boguslawska M, Kiejna A, Beszlej JA, Orzechowska-Juzwenko K, Milejski P: Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4. [PubMed:15520506]
  2. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004 Jul;60(5):329-36. Epub 2004 May 28. [PubMed:15168101]
  3. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]
  4. Haritos VS, Ghabrial H, Ahokas JT, Ching MS: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000 Oct;10(7):591-603. [PubMed:11037801]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]
  2. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]
  2. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536]
  2. Haritos VS, Ghabrial H, Ahokas JT, Ching MS: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000 Oct;10(7):591-603. [PubMed:11037801]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:53